Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $117,783 | 9 | 100.0% |
| Food and Beverage | $12.90 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $117,783 | 9 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $12.90 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $117,783 | 9 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($117,783) |
| 2017 | $12.90 | 1 | Merck Sharp & Dohme Corporation ($12.90) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,892.40 | General |
| 12/16/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $14,523.20 | General |
| 11/03/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $14,523.20 | General |
| 09/25/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $18,154.00 | General |
| 08/21/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $12,376.00 | General |
| 08/21/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,178.48 | General |
| 07/29/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $14,560.00 | General |
| 07/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $16,016.00 | General |
| 05/28/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $14,560.00 | General |
| 02/03/2017 | Merck Sharp & Dohme Corporation | NEXPLANON (Drug) | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: WOMENS HEALTH | ||||||
About Dr. Celia Ezidiegwu, MD
Dr. Celia Ezidiegwu, MD is a Family Medicine healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2016. The National Provider Identifier (NPI) number assigned to this provider is 1215389713.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Celia Ezidiegwu, MD has received a total of $117,796 in payments from pharmaceutical and medical device companies, with $117,783 received in 2020. These payments were reported across 10 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($117,783).
Practice Information
- Specialty Family Medicine
- Location Philadelphia, PA
- Active Since 07/07/2016
- Last Updated 07/07/2016
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1215389713
Products in Payments
- NEXPLANON (Drug) $12.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Philadelphia
Dr. Michael Attanasio, D.o, D.O
Family Medicine — Payments: $263,805
Dr. Deborah Witt, M.d, M.D
Family Medicine — Payments: $226,164
Jonah Mink, Md, MD
Family Medicine — Payments: $146,427
Dr. Glenn Rosen, Md, MD
Family Medicine — Payments: $77,390
Dr. Casey Lafferty, D.o, D.O
Family Medicine — Payments: $54,627
Dr. Daniel Schwartz, Do, DO
Family Medicine — Payments: $33,185